Literature DB >> 18626733

Photodynamic therapy for polypoidal choroidal vasculopathy: vaso-occlusive effect on the branching vascular network and origin of recurrence.

Won Ki Lee1, Phil Young Lee2, Sang Kyu Lee2.   

Abstract

PURPOSE: To determine whether photodynamic therapy (PDT) has a vaso-occlusive effect on the branching vascular network in polypoidal choroidal vasculopathy (PCV) and whether PDT can prevent future recurrence.
METHODS: We analyzed pre-and post-PDT indocyanine green angiography (ICGA) results of 27 patients (27 eyes) who were diagnosed with PCV and who had shown clinical improvement accompanied by occlusion of polypoidal lesions after PDT. We also investigated the recurrent events in these patients and the origin of the recurrences.
RESULTS: The branching vascular network persisted, at least in part, in 20 (87%) of 23 eyes undergoing one PDT session and in two (50%) of four eyes undergoing two PDT sessions. In the remaining five eyes, we could not determine definitively whether the branching vessels were occluded completely. Recurrent serous changes occurred in nine eyes (33%) 14-48 months after the last PDT. ICGA revealed that these changes were caused by new polypoidal lesions that originated from further-grown branches of the persistent branching vascular network. Diffuse leakage from undetermined sources seemed to coexist in two eyes.
CONCLUSIONS: PDT cannot induce complete occlusion of the branching vascular network. PDT does not prevent future recurrence, because new active polypoidal lesions may develop from the persistent branching vessels in the network.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18626733     DOI: 10.1007/s10384-007-0501-y

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  20 in total

1.  A study of laser photocoagulation for polypoidal choroidal vasculopathy.

Authors:  Mitsuko Yuzawa; Ryuzaburo Mori; Miho Haruyama
Journal:  Jpn J Ophthalmol       Date:  2003 Jul-Aug       Impact factor: 2.447

2.  The origins of polypoidal choroidal vasculopathy.

Authors:  M Yuzawa; R Mori; A Kawamura
Journal:  Br J Ophthalmol       Date:  2005-05       Impact factor: 4.638

3.  The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy.

Authors:  L A Yannuzzi; A Ciardella; R F Spaide; M Rabb; K B Freund; D A Orlock
Journal:  Arch Ophthalmol       Date:  1997-04

4.  Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin.

Authors:  Rufino M Silva; João Figueira; M Luz Cachulo; Liliane Duarte; José R Faria de Abreu; J G Cunha-Vaz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-10-20       Impact factor: 3.117

5.  Idiopathic polypoidal choroidal vasculopathy in Japanese patients.

Authors:  M Uyama; T Matsubara; I Fukushima; H Matsunaga; K Iwashita; Y Nagai; K Takahashi
Journal:  Arch Ophthalmol       Date:  1999-08

6.  Polypoidal choroidal vasculopathy: natural history.

Authors:  Masanobu Uyama; Mitsumasa Wada; Yoshimi Nagai; Takashi Matsubara; Hiroshi Matsunaga; Ichiro Fukushima; Kanji Takahashi; Miyo Matsumura
Journal:  Am J Ophthalmol       Date:  2002-05       Impact factor: 5.258

7.  Idiopathic polypoidal choroidal vasculopathy (IPCV).

Authors:  L A Yannuzzi; J Sorenson; R F Spaide; B Lipson
Journal:  Retina       Date:  1990       Impact factor: 4.256

8.  Clinicopathological correlation of polypoidal choroidal vasculopathy revealed by ultrastructural study.

Authors:  A Okubo; M Sameshima; A Uemura; S Kanda; N Ohba
Journal:  Br J Ophthalmol       Date:  2002-10       Impact factor: 4.638

9.  Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy.

Authors:  R F Spaide; L A Yannuzzi; J S Slakter; J Sorenson; D A Orlach
Journal:  Retina       Date:  1995       Impact factor: 4.256

10.  Exudative idiopathic polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin.

Authors:  Maddalena Quaranta; Martine Mauget-Faÿsse; Gabriel Coscas
Journal:  Am J Ophthalmol       Date:  2002-08       Impact factor: 5.258

View more
  17 in total

1.  Transitions of multifocal electroretinography following combined intravitreal bevacizumab and photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Chengguo Zuo; Feng Wen; Jiaqing Li; Yan Liu; Meng Li
Journal:  Doc Ophthalmol       Date:  2009-01-31       Impact factor: 2.379

2.  Characteristics of fine vascular network pattern associated with recurrence of polypoidal choroidal vasculopathy.

Authors:  A Oishi; M Mandai; M Kimakura; A Nishida; Y Kurimoto
Journal:  Eye (Lond)       Date:  2011-05-06       Impact factor: 3.775

3.  Bevacizumab for serous changes originating from a persistent branching vascular network following photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Kyu Seop Kim; Won Ki Lee
Journal:  Jpn J Ophthalmol       Date:  2011-06-07       Impact factor: 2.447

4.  Anti-vascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy with polyps resembling grape clusters.

Authors:  Jae Hyung Lee; Won Ki Lee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-07-03       Impact factor: 3.117

5.  Factors associated with polyp regression after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy.

Authors:  Han Joo Cho; Sang Yoon Han; Hyoung Seok Kim; Tae Gon Lee; Jong Woo Kim
Journal:  Jpn J Ophthalmol       Date:  2014-11-07       Impact factor: 2.447

6.  Time-lag between subretinal fluid and pigment epithelial detachment reduction after polypoidal choroidal vasculopathy treatment.

Authors:  Ju Byung Chae; Joo Yong Lee; Sung Jae Yang; June-Gone Kim; Young Hee Yoon
Journal:  Korean J Ophthalmol       Date:  2011-03-11

7.  Quantitative analysis of branching neovascular networks in polypoidal choroidal vasculopathy by optical coherence tomography angiography after photodynamic therapy and anti-vascular endothelial growth factor combination therapy.

Authors:  Wen-Yi Wang; Chang-Hao Yang; Ta-Ching Chen; Yi-Ting Hsieh; Tzyy-Chang Ho; Chung-May Yang; Fang-Yu Liu; Tso-Ting Lai
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-02-08       Impact factor: 3.117

8.  Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial.

Authors:  Adrian Koh; Timothy Y Y Lai; Kanji Takahashi; Tien Y Wong; Lee-Jen Chen; Paisan Ruamviboonsuk; Colin S Tan; Chrystel Feller; Philippe Margaron; Tock H Lim; Won Ki Lee
Journal:  JAMA Ophthalmol       Date:  2017-11-01       Impact factor: 7.389

Review 9.  Verteporfin PDT for non-standard indications--a review of current literature.

Authors:  Wai Man Chan; Tock-Han Lim; Alfredo Pece; Rufino Silva; Nagahisa Yoshimura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-02-17       Impact factor: 3.117

10.  Polypoidal Choroidal Vasculopathy.

Authors:  Joon-Bom Kim; Rajinder S Nirwan; Ajay E Kuriyan
Journal:  Curr Ophthalmol Rep       Date:  2017-04-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.